Curia Expands Cell Line Development Offering with CHOZN Platform

Curia, a contract research, development, and manufacturing organization (CDMO), signed a licensing agreement with MilliporeSigma that enables Curia and its clients to use the CHOZN GS-/- cell line for production of therapeutic proteins and antibodies. Following the agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers.

CHOZN platform is a Chinese Hamster Ovary (CHO) mammalian cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for production of biologics and therapeutic recombinant proteins. It includes high-performing CHO cell lines, paired media and feeds, optimized expression vectors and robust protocols. The glutamine synthetase GS knockout (GS-/-) cell line of the CHOZN platform is specially designed to help streamline selection, identification and scale-up of high-producing clones ideal for GMP manufacturing of recombinant protein drugs.

The addition of the CHOZN platform strengthens Curia’s offerings as a complement to its existing proprietary CHO cell line.

“We continue to strengthen our biologics development offerings from discovery through clinical manufacturing,” said Christopher Conway, President R&D, Curia. “The CHOZN GS-/- cell line platform adds a widely accepted and commercially viable cell line to our capabilities. Our integrated offering accelerates therapeutic protein and antibody production and offers seamless tech transfer for optimal flexibility.”